MRX-6

Inflammatory skin diseases (Dermatitis)

Morria's MFAIDs target inflammatory mediators that play a key role in skin inflammation, a $3bn annual market.
Pilot studies in patients suffering from contact dermatitis have been successfully completed and demonstrate marked efficacy compared to a placebo. Eleven patients were topically administered MRX-6 twice daily for 28 days in a double blind, placebo controlled first-in-patient pilot study. MRX-6-treated subjects showed a 69% improvement compared to just 32% improvement in placebo-treated subjects. An 80 patient study is currently underway.

References:
Ingber A, Cohen Y, Krimsky M, Yedgar S. A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.